Servier in the news
Patient-Centric Drug Development R&D
Tamtam found 20 recent articles about Servier.
- Servier Pharmaceuticals Connects Healthcare Professionals Around pLGG at SNO 2026
Servier Pharmaceuticals organized a gathering of healthcare professionals and advocates at SNO 2026 to discuss and advance care for pediatric low-grade glioma (pLGG).
- SERVIER CANADA WINS THE 2026 PRIX GALIEN INNOVATIVE PRODUCT AWARD
Servier Canada received the 2026 Prix Galien Innovative Product Award for Voranigo, a new oral treatment for Grade 2 IDH-mutant glioma, a rare brain cancer.
- Servier Announces Updated Four-Year Results for OJEMDA in Pediatric Low-Grade Glioma
Servier released updated four-year results from its Phase 2 FIREFLY-1 study on OJEMDA for pediatric low-grade glioma, showing prolonged time off treatment and a consistent safety profile.
- Servier Presents Long-Term INDIGO Analyses Demonstrating Sustained Clinical Benefit of VORANIGO® (vorasidenib) in IDH-Mutant Glioma Across Subgroups at SNO 2026
Servier presented long-term data at SNO 2026 showing VORANIGO (vorasidenib) provides sustained clinical benefits, improved tumor response, and better quality of life for patients with IDH-mutant glioma.
- Myopathies de Becker et de Duchenne : des résultats décevants poussent Servier à arrêter les essais
Servier discontinues sevasemten clinical trials for Becker and Duchenne muscular dystrophies after the Grand Canyon study failed to show statistically significant benefits.
- Hani Friedman Bouganim Highlights Servier Gidy’s Role in French Industry Week
Servier Gidy showcased its industrial operations and community engagement during French Industry Week, emphasizing expertise, local cooperation, and patient supply.
- Servier : des hackers menacent de dévoiler les données de plus de 17 000 patients atteints de cancer
French pharmaceutical giant Servier faces a cyberattack threat from N0n, which claims to possess sensitive medical data of over 17,000 US cancer patients, though the data's authenticity is unconfirmed.
- Servier Laboratories : fuite de données
The N0N ransomware group claims to possess over 35,000 medical records from Servier Laboratories concerning more than 17,000 oncology patients, threatening publication if no settlement is reached, though the authenticity remains unconfirmed.
- Servier Presents Updated Four-Year Results from Phase 2 FIREFLY-1 Study of OJEMDA® (tovorafenib) in Pediatric Low-Grade Glioma (pLGG) at SNO 2026
Servier announced updated four-year results for OJEMDA (tovorafenib) in pediatric low-grade glioma, demonstrating sustained efficacy and a consistent safety profile.
- Servier arrête le développement d'un traitement expérimental contre les dystrophies musculaires
Servier discontinues the development of sevasemten, a treatment for muscular dystrophies, due to failed clinical trials.
- Lea Rauch appointed General Manager of Servier Pharma Romania
Léa Rauch has been appointed General Manager of Servier Pharma Romania, where she will lead the company's development, focusing on strengthening therapeutic areas and improving patient access to medicines.
- Statement from the Muscular Dystrophy Association on Servier’s Decision to Discontinue Sevasemten Development for Duchenne Muscular Dystrophy
Servier discontinues development of sevasemten for Duchenne muscular dystrophy after clinical trials showed insufficient efficacy.
- “It All Starts Here”: Servier highlights its commitment in Europe
Servier highlights its extensive European research, development, and manufacturing capabilities through a new campaign and reinvests profits into these activities.
- « Tout commence ici » : Servier met en lumière son engagement en Europe
Servier launched a campaign to promote its extensive European drug development and production footprint, showcasing its reinvestment of profits into R&D and commitment to local investment across multiple sites.
- Walid Kamoun: What Makes the Servier and Insilico Medicine Partnership So Powerful?
Servier and Insilico Medicine are advancing their oncology collaboration, with one program reaching an inflection point and another being nominated.
- Claude Bertrand Discusses Servier’s Expanding Partnerships and R&D Opportunities in China
Servier is expanding R&D partnerships in China, aiming to integrate its dynamic innovation ecosystem into Servier's global network.
- Global Colleagues Join Servier Portugal to Discuss Oncology Priorities and Clinical Research
Servier Portugal hosted a global oncology business review to discuss strategy, ambitions, and opportunities for advancing cancer research and patient care.
- Presenting New Neuro-Oncology Data Across 9 Presentations at SNO 2026 - Servier Pharmaceuticals
Servier Pharmaceuticals is presenting new neuro-oncology data at the 2026 Society for Neuro-Oncology Annual Meeting in Philadelphia, focusing on advancements for patients with glioma.
- Servier Highlights Growing Neuro-Oncology Portfolio with New Data Across Pediatric and Adult Glioma at SNO 2026
Servier will present new clinical and real-world data for its neuro-oncology portfolio, including OJEMDA and VORANIGO, at the upcoming SNO Annual Meeting, highlighting advancements in treating pediatric and adult glioma.
- Servier mise sur l’Égypte pour la production et la commercialisation de ses médicaments
Servier plans to produce and commercialize its drugs in Egypt.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Servier?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies